Related Experiment Video

Updated: May 14, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies

Kim-Hien T Dao1, Jeffrey W Tyner

  • 1Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland 97239, Oregon, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 6, 2013
PubMed

Insights

Disease relapse in BCR-ABL-positive leukemia is a major cause of death. Targeting leukemia stem cell pathways offers a promising strategy for eradication or enhancing current therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Leukemia relapse is a significant challenge in BCR-ABL-positive leukemia treatment.
  • Kinase inhibitors have improved outcomes but have not eliminated disease recurrence.
  • Leukemia stem cells (LSCs) are implicated in treatment resistance and relapse.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting pathways essential for LSC survival.
  • To investigate methods for definitive eradication of leukemia stem cells.
  • To enhance the efficacy of existing leukemia therapies.

Main Methods:

  • Investigating key molecular pathways maintaining LSC function.
  • Developing targeted agents against identified LSC-specific vulnerabilities.
  • Preclinical validation of therapeutic approaches in relevant leukemia models.

Main Results:

  • Identification of critical pathways supporting LSC persistence.
  • Demonstration of LSC targeting as a viable strategy.
  • Potential for combination therapies to improve eradication rates.

Conclusions:

  • Targeting leukemia stem cell pathways is crucial for overcoming relapse in BCR-ABL-positive leukemia.
  • This approach holds promise for achieving durable remissions and improving patient survival.
  • Further research into LSC biology can lead to more effective leukemia treatments.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...